Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Humanigen Inc's Business Segments
Humanigen Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
-
Largest Segment
-
Total Revenue
$ 0
Regions Reported
-
Humanigen Inc does not report a distinct business-segment axis in its filings - its disaggregated revenue is disclosed by product and service category instead. See the Product & Service breakdown below.
Revenue by Product & Service Category - FY
- License revenue100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| License revenue | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Humanigen Inc
Humanigen Inc. is a biotherapeutics company headquartered in Burlingame, California. The company is focused on developing cutting-edge monoclonal antibody treatments for various diseases, including infectious diseases and cancer. Humanigen's research and development efforts are driven by their proprietary technologies and platforms that are designed to enhance the therapeutic potential of existing drugs and accelerate the development of novel treatments.
Humanigen Inc. was originally founded in 2000 under the name NexBio Inc. and rebranded as Humanigen in 201 The company has a strong track record of innovation and has made significant advancements in the field of immunology and biotechnology.
One of Humanigen's flagship product candidates is lenzilumab, a monoclonal antibody designed to neutralize and inhibit granulocyte-macrophage colony-stimulating factor (GM-CSF). Lenzilumab has shown promising results in both pre-clinical and clinical studies for various conditions, including acute respiratory distress syndrome (ARDS), a severe complication observed in patients with COVID-19. Humanigen is also exploring the potential of lenzilumab in the treatment of certain types of cancer, graft-versus-host disease (GVHD), and CAR-T therapy-related toxicities.
Humanigen's focus on leveraging GM-CSF neutralization as a therapeutic strategy sets them apart from other companies in the biopharmaceutical space. The company believes that by targeting GM-CSF, it can modulate the immune system more effectively, leading to improved clinical outcomes for patients.
Apart from lenzilumab, Humanigen has several other product candidates in its pipeline, addressing various diseases and medical conditions. This includes ifabotuzumab, an anti-EphA3 antibody, which is being studied for its potential in the treatment of acute myeloid leukemia (AML) and solid tumors. Additionally, the company is also working on proprietary technology to enhance the therapeutic potential of CAR-T cell therapies.
Humanigen has collaboration agreements with leading academic institutions, research organizations, and pharmaceutical companies, allowing them to access valuable expertise and resources required for successful drug development. The company also actively seeks partnerships and collaborations to further advance its pipeline and expand the applications of its technologies.
In addition to its product candidates, Humanigen is committed to addressing unmet medical needs globally. The company is actively involved in humanitarian efforts and has launched the Stop ARDS initiative to raise awareness about ARDS and support research that can lead to better treatment options for the condition.
Overall, Humanigen Inc. is a biotechnology company at the forefront of developing innovative monoclonal antibody therapies. Their focus on GM-CSF neutralization and proprietary technologies positions them as a key player in the biopharmaceutical industry, with the potential to make significant contributions to patient care and outcomes.
Humanigen Inc. was originally founded in 2000 under the name NexBio Inc. and rebranded as Humanigen in 201 The company has a strong track record of innovation and has made significant advancements in the field of immunology and biotechnology.
One of Humanigen's flagship product candidates is lenzilumab, a monoclonal antibody designed to neutralize and inhibit granulocyte-macrophage colony-stimulating factor (GM-CSF). Lenzilumab has shown promising results in both pre-clinical and clinical studies for various conditions, including acute respiratory distress syndrome (ARDS), a severe complication observed in patients with COVID-19. Humanigen is also exploring the potential of lenzilumab in the treatment of certain types of cancer, graft-versus-host disease (GVHD), and CAR-T therapy-related toxicities.
Humanigen's focus on leveraging GM-CSF neutralization as a therapeutic strategy sets them apart from other companies in the biopharmaceutical space. The company believes that by targeting GM-CSF, it can modulate the immune system more effectively, leading to improved clinical outcomes for patients.
Apart from lenzilumab, Humanigen has several other product candidates in its pipeline, addressing various diseases and medical conditions. This includes ifabotuzumab, an anti-EphA3 antibody, which is being studied for its potential in the treatment of acute myeloid leukemia (AML) and solid tumors. Additionally, the company is also working on proprietary technology to enhance the therapeutic potential of CAR-T cell therapies.
Humanigen has collaboration agreements with leading academic institutions, research organizations, and pharmaceutical companies, allowing them to access valuable expertise and resources required for successful drug development. The company also actively seeks partnerships and collaborations to further advance its pipeline and expand the applications of its technologies.
In addition to its product candidates, Humanigen is committed to addressing unmet medical needs globally. The company is actively involved in humanitarian efforts and has launched the Stop ARDS initiative to raise awareness about ARDS and support research that can lead to better treatment options for the condition.
Overall, Humanigen Inc. is a biotechnology company at the forefront of developing innovative monoclonal antibody therapies. Their focus on GM-CSF neutralization and proprietary technologies positions them as a key player in the biopharmaceutical industry, with the potential to make significant contributions to patient care and outcomes.
Humanigen, Inc. is a biopharmaceutical company focused on developing innovative therapies that aim to improve outcomes for patients with various serious diseases, particularly those associated with immunological and inflammatory conditions. The company is primarily engaged in the research and development of monoclonal antibodies and other therapeutic modalities.
Segments
1. Therapeutic Development:
- Humanigens primary segment revolves around the development of therapeutic solutions that target severe inflammatory and immune-mediated diseases. Their focus includes critical conditions that often lead to high mortality rates, such as cytokine release syndrome (CRS) associated with CAR-T cell therapies and other advanced cancer treatments.
2. Oncology:
- The oncology segment targets cancers, specifically those types where the immune system plays a critical role in disease progression and where existing treatments may not offer sufficient efficacy or safety.
3. Immunology/Inflammation:
- This segment addresses diseases characterized by excessive inflammation, where the modulation of immune response can result in better patient outcomes.
Products
1. Lenzilumab:
- Lenzilumab is Humanigens leading monoclonal antibody product candidate. It is designed to inhibit granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine involved in various severe medical conditions. Lenzilumab is primarily being investigated for its efficacy in treating COVID-19, specifically in patients presenting with severe inflammatory responses and cytokine storm.
2. Gimsilumab:
- Another monoclonal antibody in development, Gimsilumab targets GM-CSF as well but is being explored for potential applications in other inflammatory conditions and hematological malignancies.
3. Other Pipeline Candidates:
- Humanigen is also pursuing additional candidates in its pipeline, aimed at addressing various serious diseases with significant unmet medical needs. The specific details of these candidates may include various stages of clinical trials and research focused on advancing their therapeutic profiles.
Services
1. Clinical Trials:
- Humanigen conducts rigorous clinical trials to evaluate the safety and efficacy of their product candidates. The company engages in partnerships and collaborations to enhance the reach and capability of its clinical development programs, encompassing Phase 1 through Phase 3 trials.
2. Consulting and Strategic Partnerships:
- Humanigen engages in strategic partnerships with other biopharmaceutical companies, academic institutions, and healthcare organizations to advance research, share resources, and collaborate on clinical development and commercialization efforts.
3. Regulatory Support:
- The company dedicates resources to navigate the regulatory landscape for drug approvals, ensuring compliance with the FDA and equivalent regulatory bodies in other markets. They work closely with regulatory agencies to facilitate the approval processes for their therapeutic candidates.
4. Manufacturing and Supply Chain:
- Humanigen may also provide services related to the manufacturing of their biologic products, focusing on ensuring quality control and compliance with Good Manufacturing Practices (GMP). This includes establishing robust supply chains for raw materials, intermediates, and final products.
5. Clinical Development Support:
- The company often provides support for the design and execution of clinical studies, including protocol development, patient recruitment strategies, and data analysis to meet clinical endpoints effectively.
Conclusion
Humanigen, Inc. operates in the highly specialized field of biopharmaceuticals, with a clear focus on developing novel treatments for life-threatening conditions driven by immune response dysregulation and severe inflammatory processes. Through its platform of monoclonal antibodies, particularly Lenzilumab, and ongoing clinical development efforts, the company aims to address critical healthcare needs and improve patient outcomes across a spectrum of serious diseases.
Segments
1. Therapeutic Development:
- Humanigens primary segment revolves around the development of therapeutic solutions that target severe inflammatory and immune-mediated diseases. Their focus includes critical conditions that often lead to high mortality rates, such as cytokine release syndrome (CRS) associated with CAR-T cell therapies and other advanced cancer treatments.
2. Oncology:
- The oncology segment targets cancers, specifically those types where the immune system plays a critical role in disease progression and where existing treatments may not offer sufficient efficacy or safety.
3. Immunology/Inflammation:
- This segment addresses diseases characterized by excessive inflammation, where the modulation of immune response can result in better patient outcomes.
Products
1. Lenzilumab:
- Lenzilumab is Humanigens leading monoclonal antibody product candidate. It is designed to inhibit granulocyte-macrophage colony-stimulating factor (GM-CSF), a pro-inflammatory cytokine involved in various severe medical conditions. Lenzilumab is primarily being investigated for its efficacy in treating COVID-19, specifically in patients presenting with severe inflammatory responses and cytokine storm.
2. Gimsilumab:
- Another monoclonal antibody in development, Gimsilumab targets GM-CSF as well but is being explored for potential applications in other inflammatory conditions and hematological malignancies.
3. Other Pipeline Candidates:
- Humanigen is also pursuing additional candidates in its pipeline, aimed at addressing various serious diseases with significant unmet medical needs. The specific details of these candidates may include various stages of clinical trials and research focused on advancing their therapeutic profiles.
Services
1. Clinical Trials:
- Humanigen conducts rigorous clinical trials to evaluate the safety and efficacy of their product candidates. The company engages in partnerships and collaborations to enhance the reach and capability of its clinical development programs, encompassing Phase 1 through Phase 3 trials.
2. Consulting and Strategic Partnerships:
- Humanigen engages in strategic partnerships with other biopharmaceutical companies, academic institutions, and healthcare organizations to advance research, share resources, and collaborate on clinical development and commercialization efforts.
3. Regulatory Support:
- The company dedicates resources to navigate the regulatory landscape for drug approvals, ensuring compliance with the FDA and equivalent regulatory bodies in other markets. They work closely with regulatory agencies to facilitate the approval processes for their therapeutic candidates.
4. Manufacturing and Supply Chain:
- Humanigen may also provide services related to the manufacturing of their biologic products, focusing on ensuring quality control and compliance with Good Manufacturing Practices (GMP). This includes establishing robust supply chains for raw materials, intermediates, and final products.
5. Clinical Development Support:
- The company often provides support for the design and execution of clinical studies, including protocol development, patient recruitment strategies, and data analysis to meet clinical endpoints effectively.
Conclusion
Humanigen, Inc. operates in the highly specialized field of biopharmaceuticals, with a clear focus on developing novel treatments for life-threatening conditions driven by immune response dysregulation and severe inflammatory processes. Through its platform of monoclonal antibodies, particularly Lenzilumab, and ongoing clinical development efforts, the company aims to address critical healthcare needs and improve patient outcomes across a spectrum of serious diseases.